<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>POLYCIN - bacitracin zinc and polymyxin b sulfate ointment </strong><br>Fera Pharmaceuticals<br></p></div>
<h1>POLYCIN</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment USP, is a sterile antimicrobial ointment for ophthalmic use.  Each gram contains: bacitracin zinc equivalent to 500 bacitracin units, polymyxin B sulfate equivalent to 10,000 polymyxin B units, mineral oil, and white petrolatum.</p>
<p></p>
<p></p>
<p>Bacitracin zinc is the zinc salt of bacitracin, a mixture of related
cyclic polypeptides (mainly bacitracin A) produced by the growth of an
organism of the <span class="Italics">licheniformis</span> group of <span class="Italics">Bacillus subtilis</span> var Tracy.  It has a potency of not less than 40 bacitracin units per mg.  The structural formula for bacitracin A is:</p>
<p><img alt="Fera Pharmaceuticals Bacitracin Zinc Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee57e9-b09c-4316-add2-66b5b06b6e79&amp;name=9c3608ed-b194-4374-af4f-0e46e821c51f-01.jpg"></p>
<p></p>
<p>Polymyxin B sulfate is the sulfate salt of polymyxin B<span class="Sub">1</span> and B<span class="Sub">2</span> which are produced by the growth of <span class="Italics">Bacillus polymyxa</span>
(Prazmowski) Migula (Fam. Bacillaceae<span class="Italics">).  </span>It has a potency of not less
than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. 
The structural formulae are:<span class="Italics"></span></p>
<p><img alt="Fera Pharmaceuticals Polymyxin B Sulfate Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee57e9-b09c-4316-add2-66b5b06b6e79&amp;name=9c3608ed-b194-4374-af4f-0e46e821c51f-02.jpg"></p>
<p></p>
<p></p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY:</h1>
<p class="First">A wide range of antibacterial action is provided by the overlapping spectra of bacitracin and polymyxin B sulfate.</p>
<p>Bacitracin is bactericidal for a variety of gram-positive and
gram-negative organisms.  It interferes with bacterial cell wall
synthesis by inhibition of the regeneration of phospholipid receptors
involved in peptidoglycan synthesis.<br></p>
<p>Polymyxin B is bactericidal for a variety of gram-negative organisms.  It increases the permeability of the bacterial cell membrane by interacting with the phospholipid components of the membrane.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-3"></a><p></p>
<h1>Microbiology:</h1>
<p class="First">Bacitracin zinc and polymyxin B sulfate together are considered active against the following microorganisms:  <span class="Italics">Staphylococcus aureus</span>, streptococci including <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella/Enterobacter</span> species, <span class="Italics">Neisseria</span> species and <span class="Italics">Pseudomonas aeruginosa</span>.  The product does not provide adequate coverage against <span class="Italics">Serratia marcescens</span><span class="Bold">.<br></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE:</h1>
<p class="First">Polycin<span class="Sup">TM</span> Ophthalmic Ointment is indicated for the topical treatment of superficial <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the external eye and its adnexa caused by susceptible bacteria.  Such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> encompass <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> and <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratoconjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span> and <span class="product-label-link" type="condition" conceptid="374347" conceptname="Blepharoconjunctivitis">blepharoconjunctivitis</span>.<br></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS:</h1>
<p class="First">Polycin<span class="Sup">TM</span> Ophthalmic Ointment is contraindicated in individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components.<br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS:</h1>
<p class="First">NOT FOR INJECTION INTO THE EYE.  Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment should never be directly introduced into the anterior chamber of the eye.  Ophthalmic ointments may retard corneal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
<p>Topical antibiotics may cause cutaneous sensitization.  A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical antibiotics is not known.  The manifestations of sensitization to topical antibiotics are usually <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, reddening, and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the conjunctiva and eyelid.  A sensitization reaction may manifest simply, as a failure to heal.  During long-term use of topical antibiotic products, periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed.  Symptoms usually subside quickly on withdrawing the medication.  Application of products containing these ingredients should be avoided for the patient thereafter (see <span class="Bold">PRECAUTIONS: General</span>).<br></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS:</h1>
<p class="First"><br></p>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">As with other antibiotic preparations, prolonged use of Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment may result in overgrowth of non susceptible organisms including fungi.  If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate measures should be initiated.</p>
<p><span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">Bacterial resistance</span> to Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment may also develop.  If <span class="product-label-link" type="condition" conceptid="4145093" conceptname="Purulent discharge">purulent discharge</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> become aggravated, the patient should discontinue use of the medication and consult a physician.</p>
<p>There have been reports of bacterial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> associated with the use of topical ophthalmic products in multiple-dose containers which have been inadvertently contaminated by patients, most of whom has a concurrent corneal disease or a disruption of the ocular epithelial surface (see <span class="Bold">PRECAUTIONS: Information for Patients</span>).</p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>:  kanamycin, paromomycin, streptomycin, and possibly gentamicin.<br></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye, eyelid, fingers, or any other surface.  The use of this product by more than one person may spread <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Patients should also be instructed that ocular products, if handled improperly, can become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated products (see <span class="Bold">PRECAUTIONS: General</span>).</p>
<p>If the condition persists or gets worse, or if a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> develops, the patient should be advised to stop use and consult a physician.  Do not use this product if you are allergic to any of the listed ingredients.  Keep tightly closed when not in use.  Keep out of reach of children.<br></p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h2>
<p class="First">Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with polymyxin B sulfate or bacitracin.  Polymyxin B has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.  No adverse effects on male or female fertility, litter size, or survival were observed in rabbits given bacitracin zinc 100 gm/ton of diet.<br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2>Pregnancy:</h2>
<p class="First"><br></p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5"></a><p></p>
<h2>Teratogenic Effects:  Pregnancy Category C.</h2>
<p class="First">Animal reproduction studies have not been conducted with polymyxin B sulfate or bacitracin.  It is also not known whether Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment should be given to a pregnant woman only if clearly needed.<br></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers:</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is administered to a nursing woman.<br></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS:</h1>
<p class="First">Adverse reactions have occurred with the anti-infective components of Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment.  The exact incidence is not known.  Reactions occurring most often are allergic sensitization reactions including <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, and conjunctival <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> (see <span class="Bold">WARNINGS</span>).  More serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported rarely.</p>
<p>Local irritation on instillation has also been reported.</p>
<p><span class="Italics">To report SUSPECTED ADVERSE REACTIONS, contact Fera Pharmaceuticals, LLC at (414) 434-6604, Monday-Friday 9am-5pm EST, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<br></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION:</h1>
<p class="First">May be applied every 3 or 4 hours for 7 to 10 days, depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:</h1>
<p class="First">Polycin<span class="Sup">TM</span> Ophthalmic Ointment is supplied in 3.5 g (1/8 oz) sterile tamper evident tubes with ophthalmic tip.</p>
<p><br>NDC 48102-004-35</p>Store at 20<span class="Sup">o</span>-25<span class="Sup">o</span>C (68<span class="Sup">o</span>-77<span class="Sup">o</span>F) [See USP Controlled room temperature].<br><p>Polycin<span class="Sup">TM</span> is a Trademark of Fera Pharmaceuticals, LLC.<span class="Sup"></span></p>
<br><p><span class="Bold">FERA</span></p>
<p>Mfd. for:</p>
<p><span class="Bold">Fera Pharmaceuticals, LLC</span></p>
<p>Locust Valley, NY  11560</p>
<br>PF00435A<br>R0311<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>Principal Display Panel - Carton Label</h1>
<p class="First"><br></p>
<p><img alt="Fera Pharmaceuticals Polycin Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee57e9-b09c-4316-add2-66b5b06b6e79&amp;name=9c3608ed-b194-4374-af4f-0e46e821c51f-03.jpg"></p>
<p>FERA</p>
<p>NDC 48102-004-35</p>
<p>STERILE  Rx only</p>
<p>Polycin<span class="Sup">TM</span><br></p>
<p>bacitracin zinc and</p>
<p>polymyxin B sulfate<br></p>
<p>Ophthalmic</p>
<p>Ointment USP</p>
<p>Net wt. 3.5 g (1/8 oz)</p>
<p><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>Principal Display Panel - Tube Label</h1>
<br><p class="First"><img alt="Fera Pharmaceuticals Polycin Tube Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=7eee57e9-b09c-4316-add2-66b5b06b6e79&amp;name=9c3608ed-b194-4374-af4f-0e46e821c51f-04.jpg"></p>
<p>FERA</p>
<p>NDC 48102-004-35</p>
<p>STERILE     Rx only</p>
<p>Polycin<span class="Sup">TM</span><br></p>
<p>bacitracin zinc and</p>
<p>polymyxin B sulfate<br></p>
<p>Ophthalmic</p>
<p>Ointment <br></p>
<p>USP</p>
<p>Each gram contains:</p>
<p>bacitracin zinc equivalent to <br></p>
<p>500 bacitracin units, polymyxin <br></p>
<p>B sulfate equivalent to 10,000 <br></p>
<p>polymyxin B units, mineral oil<br></p>
<p>and white petrolatum.</p>
<p>Net wt. 3.5 g (1/8 oz)<br></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POLYCIN 		
					</strong><br><span class="contentTableReg">bacitracin zinc and polymyxin b sulfate ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:48102-004</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BACITRACIN ZINC</strong> (BACITRACIN) </td>
<td class="formItem">BACITRACIN</td>
<td class="formItem">500 U  in 1 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">10000 U  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MINERAL OIL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PETROLATUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:48102-004-35</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3.5 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065022</td>
<td class="formItem">07/20/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fera Pharmaceuticals
							(831023713)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Fera Pharmaceuticals (831023713)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 7/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9c3608ed-b194-4374-af4f-0e46e821c51f</div>
<div>Set id: 7eee57e9-b09c-4316-add2-66b5b06b6e79</div>
<div>Version: 1</div>
<div>Effective Time: 20110721</div>
</div>
</div> <div class="DistributorName">Fera Pharmaceuticals</div></p>
</body></html>
